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ABSTRACT
Objective: A drug can replace other drugs in the same binding position in protein plasma, increasing pharmacological response due to the increased 
free drug concentration. Drug shifting is critical when a compound is tightly bound to a protein. For example, a binding fraction change, from 98% to 
94%, may increase the free fraction 3 times, from 2% to 6%. Knowing that there is an interaction between mefenamic acid and piroxicam on plasma 
protein, more specifically on human albumin, this study aimed to visualize the interaction between both drugs and human albumin in silico.
Methods: This study used AutoDock4 as a molecular docking technique, obtaining binding visualizations, binding energies (ΔG), and inhibition 
constants (Ki) of both mefenamic acid-albumin and piroxicam-albumin bindings.
Results: It is shown that the ΔG and Ki of both mefenamic acid and piroxicam are −5.47 kcal/mol (98.59 µM) and −7.46 kcal/mol (3.42 µM), respectively.
Conclusions: The process of binding mefenamic acid to albumin can be substituted with piroxicam due to its higher ΔG and Ki values. It can be 
predicted that this interaction will increase the free mefenamic acid concentration in blood plasma which, in turn, enhances the therapeutic effect.
Keywords: Albumin, Mefenamic acid, Piroxicam, Molecular docking.
INTRODUCTION
The pharmacological activity of a drug depends on its concentration 
in the receptor, which is directly related to the free drug concentration 
in plasma. Changes in the free drug concentration in plasma, due to 
a result of drug interactions, can be detected in vitro by a variety of 
protein binding determination methods. In various clinical conditions, 
measurements of total drug concentrations do not provide necessary 
information about the fraction of the free drug in plasma that is available 
for distribution, elimination, and pharmacodynamics action. Thus, 
accurate measurement of the concentration of free drug in the plasma 
is very important in clinical supervision. Free drug concentration 
in plasma is affected by changes in drug–protein binding. A drug’s 
plasma protein binding is critical to its clinical pharmacokinetics and 
pharmacodynamics, which are described by drug–protein binding 
parameters including the number of types of binding sites, the number 
of binding sites, and the affinity or strength of drug–protein binding [1].
A drug can shift other drugs from its binding to plasma proteins, causing 
a sudden increase of pharmacologic response due to an increase in the 
concentration of the free drug. Drug shifting is very important when the 
compound is strongly bound to the protein. A change in binding from 
98% to 94% may increase the fraction of the free drug by 3 times, from 
2% to 6%. As for the drug that weakly bounded to plasma proteins, it will 
experience a decrease in its protein binding and cause an insignificant 
clinical increase of its pharmacological activity [1]. A previous study 
provides proof that interactions between two drugs in plasma proteins 
binding are very important. Many methods are available to determine 
the amount of drug bound to plasma proteins, however, in the clinical 
evaluation of drug therapy, equilibrium dialysis, and ultrafiltration are 
the most commonly used methods. These methods are proven to be 
reliable in providing data on protein binding [1].
The drugs used in this study were mefenamic acid and piroxicam. 
Piroxicam is a nonsteroidal anti-inflammatory (NSAIDs) drug, 
while mefenamic acid is an analgesic drug that is widely used in the 
Indonesian community. Both are weak acids, thus they have a greater 
affinity for binding to albumin. The use of both analgesic and NSAIDs 
simultaneously, as pain killers for rheumatic disease, allows for an 
interaction between the two drugs in the plasma, which is associated 
to their binding to albumin. Studies on the interaction between the 
two drugs are useful for the development of both the drugs and may 
serve as useful information for health-care practitioners about their 
safety for patients [1]. Our previous in vitro study by Djajadisastra 
suggested an interaction that occurred between mefenamic acid and 
piroxicam in binding to albumin when given simultaneously. The 
percentage of albumin bound to mefenamic acid was 98.53% with 
a constant association of 1.24×105 l/mol, while the percentage of 
piroxicam bound to albumin was 95.06% with a constant association 
of 4.36×104 l/mol. When mefenamic acid and piroxicam were 
administered simultaneously, the percentage of piroxicam bound to 
albumin increased from 95.06% to 96.71%, while mefenamic acid 
decreased from 98.53% to 95.39%. However, the mechanism of the 
interaction cannot be explained [1]. Thus, in the current in silico study, 
we investigated the interaction between mefenamic acid and piroxicam 
in binding to albumin. In silico experiments with a molecular docking 
method were performed with AutoDock4 software to determine 
parameters that play important roles in the binding of mefenamic acid 
and piroxicam to human albumin.
METHODS
Instrument and software
Computer with specs of at least one gigabyte of RAM memory and 
PyMOL, Vega ZZ, Collaborative Computational Project 4 (CCP4), Cygwin, 
and AutoDock software installed were used. The structures used were:
1. A three-dimensional structure of human albumin was downloaded 
from the PDB with PDB identities 1AO6, 1BM0, and 1E78.
2. A three-dimensional structure of mefenamic acid was downloaded 
from PubChem.
3. A three-dimensional structure of piroxicam was downloaded from 
PubChem.
Separation of chain crystal structures in 1AO6, 1BM0, and 1E78
Crystal structure albumin consists of two chains, namely, A and B. For 
the docking process; we used one of the chains. When separating the 
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albumin chains in the crystal structure, PyMOL software was used to 
obtain a crystal structure of the 1AO6 chain A and B, 1BM0 chain A 
and B, as well as the 1E78 chain A and B.
Superposing crystal structure 1AO6, 1BM0, and 1E78
Based on a virtual screening study, the crystal structure of 1E78 
chain A was used. The reason to use this crystal structure is because 
the preliminary studies had been done and showed that 1E78 chain 
A had highest binding affinity score. This chain was later superposed 
with the crystal structures of 1E78 chain B, 1AO6 chain A and B, and 
1BM0 chain A and B, using CCP4 software that generates a file with the 
extension _lsq.pdb.
Depreciation of energy (energy minimization) and determination 
of the best conformation of ligand structure
The energy of mefenamic acid and piroxicam ligands used for molecular 
docking were minimized using the Vega ZZ software that accepts input, 
in the form of ligands, in any files. In this step, a hydrogen atom was 
added to each ligand structure, which was then calculated for their 
potentiality using the SP4 force field and Gasteiger charge calculation. 
The release of energy was performed using the Minimization Step Trust 
1000 program and Toler 0.01. Determination of the best conformation 
was performed using a conformational search. The result was stored in 
the. pdb file.
Development of ligand and macromolecule files
The best ligand conformation result from Vega ZZ was input into 
AutoDockTools to create a.pdbqt output file. Hydrogen was added to 
the polar macromolecules. The charges were calculated by computing 
Gasteiger charges, and the process was continued with the addition of 
nonpolar hydrogen.
Development of grid parameter file
A grid parameter in an AutoGrid4 module was used to describe the 
region of the receptor and ligand type for calculating its potentiality. 
A ligand consists of an electrostatic map; a desolvation map; and 
specific, separate atoms. Since ligand type is dependent on atom type, 
map choice was based on the type of ligand preferred. After the type of 
ligand was selected, the size of the grid box was determined. The grid 
box defines the magnitude of the molecular docking area. Determination 
of the grid box was based on the dimensions of the 1E78 chain A. The 
grid box must be able to accommodate a molecule as it rotates freely, 
generally, twice the distance of the farthest atom and the ligand binding 
site covers an area of macromolecules.
The docking technique used was blind docking, a technique in which the 
ligand docking is oriented to the entire surface of the macromolecules 
target, in this case, albumin. Based on the dimensions of albumin, the 
160×160×60 grid points box size was used, with a point measuring 
0.500 Å [2]. The development of grid parameters was done using the 
AutoDockTools grid program which utilizes ligand and macromolecule 
input from a.pdbqt file, resulting in a. gpf file output. This gpf file was 
then used as an input file to obtain a grid map with the AutoGrid4 
command on Cygwin (Table 1).
Determination of docking parameters
Determination of docking parameters was performed using 
AutoDockTools, which utilizes ligands and macromolecule inputs in a. 
pdbqt file to produce a. dpf output file (docking parameter file). The 
parameters used to determine docking parameters are the default 
parameters contained in the docking program. The algorithm used 
was the Lamarckian genetic algorithm (LGA) with 100 GA runs and 
the maximum number of energy evaluations (25 million). This dpf 
file was then used as an input to get the docking results using the 
AutoDock4 command on Cygwin (Table 1). Each ligand-macromolecule 
combination was performed repeatedly.
Analysis of docking results
The docking analysis was in a. dlg file that records details about the 
input file, the number of runs in the docking, the docking structure 
found at the end of each run, free energy (ΔG) of each conformation 
tethering, and inhibition constant values. At the end of the dlg file, 
there is a summary of the docking (Figs. 1 and 2). Docking results were 
arranged in groups called clusters. Each run, which has similarities 
in terms of the value of the free energy and conformation to active 
sites, are contained in a single cluster (Fig. 1 and 2). These clusters 
indicate the spread of data from 100 conformations docking results, 
thus called the best cluster and best dock (Table 2). Convergent results 
were generated when there was only the best cluster available (Fig. 2). 
Meanwhile, divergent results were generated when the best dock and 
best cluster were available in separate clusters (Fig. 1).
When each experiment only resulted in convergent results, the one 
with the lowest free energy was chosen. In the case that divergent 
data were obtained, the experiment with the smallest cluster best 
dock and cluster best cluster free energy was chosen. The experiment 
with posing (conformation), scoring (free energy value), and the best 
percentage was further analyzed. An experiment, visually chosen, was 
analyzed at its active site using a molecular visualization program 
PyMOL. Hydrogen bonding between ligands with macromolecules was 
also analyzed manually with PyMOL software.
RESULTS
Separation of crystal structure
The crystal structure of 1AO6, 1BM0, and 1E78 has two subunits, A 
and B. The process of “Program, Edit, File, GDP” in the CCP4 program 
separated the subunits in each crystal, resulting in crystal structures 
1AO6 chain A and B, 1BM0 chain A and B, and 1E78 chain A and B. Crystal 
structure 1E78 chain A was used as a macromolecule target based on 
the structural similarity of the three existing albumin structures.
Table 1: AutoGrid4 command on cygwin
1.autogrid4 –p 1E78_chainA.gpf –l 1E78_chainA.glg &
input: 1E78_chainA.gpf
output: 1E78_chainA.maps.fld, 1E78_chainA.maps.xyz, 1E78_chainA.
glg,
1E78_chainA.A.map, 1E78_chainAN.map, 1E78_chainA.HD.map, 
1E78_chainA.OA.map, 1E78_chainA.d.map, 1E78_chainA.e.map
2. autodock4 –p 1E78_chainA.dpf –l 1E78_chainA.dlg &
input: 1E78_chainA.dpf
output : 1E78_chainA.dlg
Table 2: Result of molecular docking
Ligand Trial Posing category ΔG (kkal/mol) Percentage Ki (µM)
Mefenamic acid Trial I Best dock −6.13 4 32.27
Best cluster −5.43 45 104.05
Trial II Best dock −6.36 7 21.65
Best cluster 5.47 35 98.59
Piroxicam Trial I Best dock −7.82 84 1.84
Best cluster −7.82 84 1.84
Perc II Best dock −7.46 51 3.42
Best cluster −7.46 51 3.42
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Superposing crystal structure 1AO6, 1BM0, and 1E78
Results of superposing the collection of CCP4 programs from the 1E78 
A and B chains showed a root-mean-square deviation (RMSD) value 
of 0.566 Å (Table 3). This value explains that there is no significant 
difference in the two structures (RMSD <2 Å).
Decrease of energy (energy minimization) and determination of 
best conformation of ligand structure
Vega ZZ software produced the best conformation of mefenamic acid 
and piroxicam with the lowest energy. The lowest energy showed the 
spontaneous binding between mefenamic acid and piroxicam with 
the receptors. The best conformation with the lowest energy is very 
important in the process to obtain the best molecular docking results.
Development of ligand and macromolecule files
AutoDockTools produced ligands and macromolecules in. pdbqt files, 
making them ready to be used as input for the docking process. This 
was due to the AutoDock docking process only accepting. pdbqt files 
as input [3,4].
Development of grid parameter file
Each ligand has a map E (electrostatic) and map D (desolvation). All 
files have the extension.map. In addition, AutoGrid4 also generates files 
with the extensions. glg., maps. fld, and. maps. xyz. The result of grid 
optimization was a grid map of specific atoms on the ligand type, with 
amounts depending on the type of atoms present in the ligand, as well 
as the electrostatic and desolvation map [5].
Development of docking parameter file
A docking parameter file was generated with AutoDockTools and has a 
file extension. dpf. This file contains parameters used in docking.
Analysis of docking results
The results of molecular docking were included in the. dlg file. Docking 
of mefenamic acid to the 1E78 chain A gave divergent results (Fig. 2). 
The posing of mefenamic acid has smallest free energy clusters, best 
cluster, and cluster best dock located in different clusters (Fig. 1). 
Piroxicam has relatively convergent results on the 1E78 chain A, where 
the posing of piroxicam with the smallest free energy clusters, best 
clusters, and cluster best dock was in one cluster (Fig. 2).
DISCUSSION
Albumin has been known to be a primary drug transport and has 
become the subject of binding studies and drug interactions. One of 
the expected drug interactions that occur in albumin is mefenamic 
acid and piroxicam competing to bind to albumin, leading to an 
increased therapeutic dose concentration of mefenamic acid in the 
blood [1]. In silico molecular tethering is used as a method to analyze 
the interaction between mefenamic acid and piroxicam when they are 
molecularly bound to albumin, confirming the interactions that occur 
between the two drugs.
Current molecular docking in AutoDockTools primarily uses default 
parameters. Exceptions to this are the number of conformation results 
from a single molecular docking (100) and the amount of energy used to 
run the docking process evaluated using a LGA docking algorithm [3,4]. 
Each conformation generated was grouped into clusters based on the 
value of the RMSD, with a maximum tolerance RMSD value of each 
member in the cluster being 2 Å. The results of the docking were then 
Table 3: Summary of 3D superposed structure of albumin




1AO6 chain A 1AO6 chain B 0.357
1BM0 chain A 1BM0 chain B 0.278
1E78 chain A 1E78 chain B 0.566
Fig. 1: (a and b) Result of albumin-mefenamic acid complexes
ba
Fig. 2: (a and b) Result of albumin-piroxicam complexes
ba
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selected based on the criteria of energy and geometry match quality. 
The ligand structure that was used for docking analysis was optimized 
using the SP4 force field in the Vega ZZ software.
The 3D structures used in this study were the crystal structures of human 
serum albumin (PDB ID: 1E78, 1AO6, and 1BM0) downloaded from the 
Protein Data Bank (PDB) website [2,6-8]. Of the three structures, 1E78 
had a larger X-ray crystallization resolution (2.60 Å) than the other 
two crystal structures. 1BM0 and 1AO6 crystal had the same R value, 
2.50 Å. Macromolecular targets affect the quality of posing and scoring 
of molecular docking thus, the selection and preparation of the structure 
model for the macromolecule target is an important variable [5].
The results of superposing 1E78, 1BM0, and 1AO6 provide three-
dimensional structural similarity (RMSD values of <2 Å), where 
superposing 1E78 and 1AO6 had a RMSD value of 0.839 Å, 1E78 and 
1BM0 had a RMSD value 0.858 Å, and 1AO6 and 1E78 had a RMSD value 
of 0.241 Å (Table 3). Due to albumin consisting of two subunits, each 
of them was superposed, resulting in three-dimensional structural 
similarity, with RMSD values of 0.357 Å, 0.278 Å, and 0.566 Å for 1AO6, 
1BM0, and 1E78, respectively (Table 3).
Mefenamic acid is a compound with three active torques, as detected 
by AutoDockTools, while piroxicam has two active torsion. The number 
of bonds that can rotate on a ligand determines the flexibility of the 
ligand [5]. Ligands’ flexibility may have greater effects on proper 
conformation predictions compared to the polarity and size of the 
ligand. Ligand flexibility is affected by posing and docking results. 
These torsion and ligand flexibility cause difficulty distinguishing 
conformational results, especially between posing with smaller free 
energy (ΔG) and a good conformation with larger free energy at the 
divergent docking results (Fig. 1).
The grid parameter file was prepared using AutoDockTools, obtaining 
a. gpf file as the output, which was then analyzed using the AutoGrid4 
command in the Cygwin program (Table 1). From this process, files with 
extensions of. glg., maps. fld, and. maps.xyz were obtained. Docking 
parameter files were prepared using the AutoDockTools program, 
obtaining a. dpf file as the output, a file that contains parameters for 
docking. The file was then applied to the Cygwin program with the 
AutoDock4 command (Table 1). The result of this process is a file with 
the extension .dlg, which stores all docking results data. From the.dlg 
file, the spread of cluster, ΔG, and Ki that are used for docking result 
analysis can be seen (Figs. 1 and 2 and Tables 2 and 4).
The best conformation of mefenamic acid, with ΔG values and Ki in the 
1E78 chain A structure was −5.47 kcal/mol and 98.59 lm, while those 
of piroxicam were −7.46 kcal/mol and 3.42 lm (Table 4). ΔG values 
describe the interaction between ligands and macromolecules. The 
smaller the value of ΔG, the smaller the energy required to occupy the 
ligand binding site, causing smaller interactions. Thus, the ligand is 
relatively more comfortable in the macromolecular targets. Meanwhile, 
the value of Ki describes the inhibition constant of ligand to bind a 
macromolecule. The smaller the value of Ki, the smaller obstacles 
that occur when a ligand binds to macromolecules will be. These 
parameters can influence the strength of bonds between the ligand 
and macromolecules, thus they can be indicators of the presence of an 
interaction between ligands in the same macromolecule.
The docking results showed that mefenamic acid bound to domain II, 
which is binding site I. Mefenamic acid bound to arginine amino acid 
at sequence 218 (R218) (Figs. 3 and 4) with 1.83 Å (Table 5). Piroxicam 
bound to the domain I, which is not a binding site I or II. Piroxicam bound 
to arginine amino acid at sequence 145 (R145) (Figs. 5 and 6) with 1.91 Å 
(Table 5). The binding that occurred was a hydrogen bond, with RMSD 
of <4 Å [6]. This suggests that mefenamic acid and piroxicam do not 
occupy the same region when binding to albumin, thus the interaction 
between mefenamic acid and piroxicam is not a competition for the 
same active site. The difference between the piroxicam and mefenamic 
acid binding sites is due to significant structural differences, shown by 
the sulfone group (SO2) in piroxicam (Fig. 7).
Table 4: Summary of free energy (ΔG) and inhibition 
constants (Ki) of selected molecular docking






1E78_chainA −5.47 −7.46 98.59 3.42
Table 5: Distance of ligand binding with macromolecules
Ligand Amino acid Bond distances (Å)
Mefenamic acid Arginine 218 1.81 & 2.03
Piroxicam Arginine 145 2.18
Mefenamic acid Lysine 195 4.84
Piroxicam Lysine 195 5.64
Fig. 4: The docking results of piroxicam to crystal structure 
1E78 chain A (100 GA runs and maximum number of energy 
evaluations [25 Million])
Fig. 3: Binding results from the docking of mefenamic acid on the 
crystal structure of 1E78 chain A (100 GA runs and maximum 
number of energy evaluations [25 Million]) 
ba
Fig. 5(a and b): Binding results from the docking of piroxicam on 
the crystal structure 1E78 chain A (100 GA runs and maximum 
number of energy evaluations [25 Million])
ba
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Results of superposing mefenamic acid-albumin and piroxicam-
albumin suggest an interaction between mefenamic acid and piroxicam 
when binding to albumin. This can be seen in the presence of lysine 
amino acid sequences that bind relatively strong in the second ligand, 
at sequence 195 (K195) (Fig. 8). This interaction allows competition 
between mefenamic acid and piroxicam when binding to albumin, where 
the bonding of mefenamic acid to albumin was 4.84 Å and piroxicam to 
albumin was 5.64 Å, which means that the distance of mefenamic acid 
to albumin was shorter than piroxicam to albumin (Table 3).
In vitro studies showed that the amount of mefenamic acid and piroxicam 
that bound to human plasma albumin was 98.53 and 95.06%, respectively. 
Mefenamic acid has a constant value of 1.24×105 l/mol when binding 
to albumin, whereas piroxicam has a value of 4.36×104 l/mol. A factor 
that causes more mefenamic acid to bind to albumin than piroxicam is 
a mefenamic acid having three primary and three secondary binding 
sites, whereas piroxicam only has one primary and three secondary 
binding sites. When mefenamic acid and piroxicam are administered 
simultaneously to bind to albumin, an interaction between the two 
drugs occurs, shown by the percentage of piroxicam binding to albumin 
increasing from 95.06% to 96.71%, while the percentage of a mefenamic 
acid binding to albumin decreased from 98.53% to 95.39%. However, the 
mechanism of the interaction cannot be explained [1].
In in silico molecular docking of mefenamic acid, used to target the 
macromolecule 1E78 chain A, mefenamic acid’s affinity to albumin 
is weaker than the affinity of piroxicam, as shown by the higher 
binding energy value of mefenamic acid (−5.47 kcal/mol) compared to 
piroxicam (−7.46 kcal/mol). The inhibition constant value of mefenamic 
acid to 1E78 chain A (98.59 lm) is much larger than piroxicam (3.42 lm) 
(Table 4). This allows the interaction between mefenamic acid and 
piroxicam when binding to albumin. Like in vitro studies, the mechanism 
of the interaction also cannot be explained.
Based on the results of molecular docking, piroxicam-albumin has a 
stronger affinity with albumin compared to mefenamic acid-albumin. In 
addition, the Ki value of piroxicam was smaller than that of mefenamic 
acid. Both parameters suggest the possibility of piroxicam replacing 
mefenamic acid, preventing it from binding to albumin. These results 
are consistent with the results of in vitro studies and suggest a possible 
interaction between mefenamic acid and piroxicam in binding to 
albumin when administered simultaneously.
CONCLUSION
Mefenamic acid and piroxicam do not occupy the same site when 
molecular docking to albumin. Mefenamic acid bound to domain II 
of albumin and piroxicam bound to domain I. However, there are 
some interactions that occur between them. The values of ΔG and Ki 
of piroxicam were smaller than mefenamic acid, allowing piroxicam 
to replace mefenamic acid in albumin binding when both drugs were 
administered simultaneously. This can increase the levels of free 
mefenamic acid in the blood, thus increasing the therapeutic effect 
of mefenamic acid. This study, however, is not without limitations. 
Further studies should be performed to investigate the active sites on 
albumin. Furthermore, the docking process time should be prolonged, 
considering the spread of some of the results were divergent.
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